Claims for Patent: 10,449,185
✉ Email this page to a colleague
Summary for Patent: 10,449,185
| Title: | Formulations of pimavanserin |
| Abstract: | Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin. |
| Inventor(s): | Tejwani; Ravi (Monmouth Junction, NJ), Abele; Stephen Edward (White Plains, NY), Vizzotti; Emanuel Joseph (Millburn, NJ) |
| Assignee: | ACADIA Pharmaceuticals Inc. (San Diego, CA) |
| Application Number: | 16/363,378 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,449,185 |
| Patent Claims: |
1. A pharmaceutically acceptable capsule for orally delivering 34 mg of pimavanserin to a patient, wherein the capsule has a capsule shell with a capsule shell size 3
or 4, that encapsulates a blended pimavanserin composition comprising: 40 mg granulated pimavanserin tartrate having a particle size distribution (D90) of 180 to 340 .mu.m, wherein the bulk density of the granulated pimavanserin is 0.4 to 0.6 g/ml as
determined by USP<616>, method 1; 59 mg microcrystalline cellulose having a particle size distribution (D90) of 180 to 340 .mu.m; and 1 mg magnesium stearate; wherein the particle size distribution is measured using laser light scattering with a
Malvern Mastersizer 2000 LLS PS system, a Scirocco 2000 dry dispersion unit and a sample size of 2 to 10 g.
2. The pharmaceutically acceptable capsule of claim 1, wherein the capsule shell is a hard shell size 4 capsule. 3. A pharmaceutically acceptable capsule for orally delivering 34 mg of pimavanserin to patient, wherein the capsule has a size 4 capsule shell that contains a blended pimavanserin composition comprising: 40% w/w pimavanserin tartrate, wherein the bulk density of the pimavanserin tartrate is 0.4 to 0.6 g/ml as determined by USP <616>, method 1; 59% w/w microcrystalline cellulose; wherein the D90 particle size distribution of the blended pimavanserin composition is 100 to 300 .mu.m as measured using laser scattering particle size analysis, and the capsule contains the 34 mg pimavanserin. 4. The pharmaceutically acceptable capsule of claim 3, wherein the blended pimavanserin composition further comprises 1% w/w magnesium stearate. 5. The pharmaceutically acceptable capsule of claim 3, wherein the capsule releases at least 80% of the pimavanserin within 30 minutes in accordance with USP <711> dissolution apparatus 1. |
